Sponsored Links 
Forest Labs Settles Patent Fight
Print
Share
Forest Laboratories Inc. (FRX - Analyst Report) and partner Merz GmbH & Co. KGaA recently entered into a patent litigation settlement agreement with about 10 companies that were seeking to launch their generic versions of Alzheimer's drug Namenda (memantine). As per the settlement agreement, the generic version of the drug will enter the market on January 11, 2015, three months before the patent expires in April 2010. This settlement agreement is subject to review by the US government.
Forest Labs and Merz settled the litigation with Watson Pharmaceuticals Inc. (WPI - Analyst Report), Dr. Reddy's Laboratories Ltd. (RDY - Snapshot Report), Mylan Inc. (MYL - Analyst Report) and Teva Pharmaceutical Industries Ltd. (TEVA - Analyst Report) among others.
Namenda is a major contributor to Forest Labs’ top-line. The product accounted for about 29% of total revenues in fiscal 2010. The drug exited fiscal 2010 with a 34.8% share of total prescriptions in the Alzheimer's market. During the recently reported first quarter of fiscal 2011, Namenda sales came in at $307.8 million, representing a year-over-year increase of 18.7%.
The company recently gained US approval for a once-daily extended-release (XR) formulation of Namenda (28 mg). Forest Labs and Merz are currently working on a suitable commercialization plan for the product.
We currently have a Neutral recommendation on Forest Labs. We remain concerned about the strength of Forest Labs’ pipeline relative to the loss in sales that will come with the Lexapro (2012) and Namenda (2015) patent expirations. With Lexapro losing patent protection in March 2012, roughly half the company’s top line will be at risk from generic competition. Given the situation, we believe that Forest Labs will continue to seek in-licensing and acquisition activities to grow its pipeline.
Forest Labs and Merz settled the litigation with Watson Pharmaceuticals Inc. (WPI - Analyst Report), Dr. Reddy's Laboratories Ltd. (RDY - Snapshot Report), Mylan Inc. (MYL - Analyst Report) and Teva Pharmaceutical Industries Ltd. (TEVA - Analyst Report) among others.
Namenda is a major contributor to Forest Labs’ top-line. The product accounted for about 29% of total revenues in fiscal 2010. The drug exited fiscal 2010 with a 34.8% share of total prescriptions in the Alzheimer's market. During the recently reported first quarter of fiscal 2011, Namenda sales came in at $307.8 million, representing a year-over-year increase of 18.7%.
The company recently gained US approval for a once-daily extended-release (XR) formulation of Namenda (28 mg). Forest Labs and Merz are currently working on a suitable commercialization plan for the product.
We currently have a Neutral recommendation on Forest Labs. We remain concerned about the strength of Forest Labs’ pipeline relative to the loss in sales that will come with the Lexapro (2012) and Namenda (2015) patent expirations. With Lexapro losing patent protection in March 2012, roughly half the company’s top line will be at risk from generic competition. Given the situation, we believe that Forest Labs will continue to seek in-licensing and acquisition activities to grow its pipeline.
Read the full analyst report on FRX
Read the full analyst report on WPI
Read the full analyst report on RDY
Read the full analyst report on MYL
Read the full analyst report on TEVA
Loading Stories...
-74.92